ChemicalBook
Chinese Japanese Germany

TICAGRELOR

Indications and Usage Mechanisms of Action Clinical Research
TICAGRELOR
TICAGRELOR
CAS No.
274693-27-5
Chemical Name:
TICAGRELOR
Synonyms
Possia;Azd 6140;Brilique;Brilinta;Ticagrelo;Ticarelor;TICAGRELOR;Tecagrelor;Ticargrelor;AR-C 126532XX
CBNumber:
CB51509134
Molecular Formula:
C23H28F2N6O4S
Formula Weight:
522.574
MOL File:
274693-27-5.mol

TICAGRELOR Properties

Density 
1.67

SAFETY

Safety Statements  24/25

TICAGRELOR price More Price(4)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Cayman Chemical 15425 Ticagrelor ≥98% 274693-27-5 5mg $25 2018-11-13 Buy
Cayman Chemical 15425 Ticagrelor ≥98% 274693-27-5 10mg $40 2018-11-13 Buy
Cayman Chemical 15425 Ticagrelor ≥98% 274693-27-5 25mg $63 2018-11-13 Buy
Cayman Chemical 15425 Ticagrelor ≥98% 274693-27-5 50mg $88 2018-11-13 Buy

TICAGRELOR Chemical Properties,Uses,Production

Indications and Usage

Ticagrelor, a new platelet aggregation inhibitor successfully developed by AstraZeneca (U.S.), is the world’s first reversible combination orally-administered P2Y12 adenosine diphosphate receptor antagonist.
It is used to reduce cardiovascular death and heart attacks in patients with acute coronary syndrome (ACS.) Rapid onset after oral administration, and can effectively improve symptoms of patients with ACS. Thienopyridines is a reversible P2Y12 inhibitor, so it is particularly applicable towards patients who need to undergo anticoagulant therapy before surgery.

Mechanisms of Action

Reversibly acts on the 2 purine receptor (purinoceptor 2, P2,) subtype P2Y12, of vascular smooth muscle cells (VSMC,) does not require metabolic activation, and has a significant inhibitory effect on platelet aggregation induced by adenosine diphosphate (ADP.)

Clinical Research

Ticagrelor was approved by the U.S. Food and Drug Administration (FDA) on the basis of PLATO clinical studies. PLATO was a 43 country, 862 center randomized, double-blind, multi-centered study which included 18,624 patients hospitalized for ACS. Patients were randomly given either aspirin plus ticagrelor, or aspirin plus clopidogrel, two antiplatelet regimens. The study showed a 16% reduction in risk of heart attack, stroke, or death in the group taking Ticagrelor compared to those who took clopidogrel. The PLATO study demonstrated the benefits of Ticagrelor for patient survival, and is currently widely recommended as a treatment strategy for ACS. In addition, at the same time it reduces operative myocardial infarction and thrombosis after stent implantation, it also does not increase the overall risk of fatal bleeding and other serious adverse effects.
Ticagrelor however has two shortcomings. First, it must be taken twice a day, compared to once a day for clopidogrel, and secondly, it may cause adverse effects such as breathing difficulties, significantly more than with the latter. Its half-life is only 12 hours, and taken twice a day, a challenge for patients with poor compliance. In practice, it has also been found that around 20% of patients treated with clopidogrel do not follow their prescriptions, and these patients are even less likely to take the prescribed doses when using ticagrelor. Thus, as a rapidly reversible drug, direct withdrawal will likely increase the risk of acute thrombosis, causing myocardial infection or stroke.

Chemical Properties

White Solid

Uses

Ticagrelor, the first reversible oral P2Y12 receptor antagonist, provides faster, greater, and more consistent ADP-receptor inhibition than Clopidogrel. Used in the treatment of acute coronary syndromes (ACS)

Uses

Ticagrelor is the first reversibly binding oral P2Y12 receptor antagonist, also inhibits CYP2C9 and 4-hydroxylation with IC50 of 10.5 μM and 8.2 μM respectively

Definition

ChEBI: A triazolopyrimidine that is an adenosine isostere; the cyclopentane ring is similar to ribose and the nitrogen-rich [1,2,3]triazolo[4,5-d]pyrimidine moiety resembles the nucleobase adenine. A platelet aggregation inhibitor which is used for p evention of thromboembolic events in patients with acute coronary syndrome.

TICAGRELOR Preparation Products And Raw materials

Raw materials

Preparation Products


TICAGRELOR Suppliers

Global( 281)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
Nanjing Gold Pharmaceutical Technology Co. Ltd.
025-84209270 15906146951
025-84209270 wgp@nanjing-pharmaceutical.com CHINA 117 55
Shanghai Yingrui Biopharma Co., Ltd.
+86-21-33585366 E-mail:sales03@shyrchem.com
+86-21-34979012 sales03@shyrchem.com CHINA 663 60
Beijing Cooperate Pharmaceutical Co.,Ltd.
+86-10-60279497 +86(0)15646567669
+86-10-60279497 sales01@cooperate-pharm.com CHINA 1529 55
Henan DaKen Chemical CO.,LTD.
+86-371-55531817
info@dakenchem.com CHINA 22060 58
Chengdu Henghui Pharm Tec Co. Ltd.
13540674322 15828370308,QQ:2879822141
028-89481236 service@2hpharm.com CHINA 121 55
Hebei Jiangkai Trading Co., Ltd
0086-17197824289/17197824028
alice@hbjkai.com CHINA 277 58
Henan Tianfu Chemical Co.,Ltd.
0371-55170693
0371-55170693 info@tianfuchem.com CHINA 20795 55
Shanghai Time Chemicals CO., Ltd.
+86-021-57951555
+86-021-57951555 jack.li@time-chemicals.com CHINA 1374 55
Nanjing ChemLin Chemical Industry Co., Ltd.
025-83697070;product@chemlin.com.cn
product@chemlin.com.cn CHINA 3015 60
ATK CHEMICAL COMPANY LIMITED
+86 21 5161 9050/ 5187 7795
+86 21 5161 9052/ 5187 7796 ivan@atkchemical.com CHINA 14297 60

View Lastest Price from TICAGRELOR manufacturers

Image Release date Product Price Min. Order Purity Supply Ability Manufacturer
2018-08-21 TICAGRELOR
274693-27-5
US $7.00 / KG 1KG 99% 1000KG career henan chemical co
2018-07-26 TICAGRELOR
274693-27-5
US $100.00 / KG 1KG 98% 100KG career henan chemical co
2018-07-26 TICAGRELOR
274693-27-5
US $100.00 / KG 1KG 98% 100KG career henan chemical co

274693-27-5(TICAGRELOR)Related Search:


  • (1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino]-5-propylsulfanyltriazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
  • Brilique
  • TICAGRELOR
  • (1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-1,2-cyclopentanediol
  • Azd 6140
  • Unii-glh0314rvc
  • (1S,2S,3R,5S)-3-(7-(((1S,2S)-2-(3,4-difluorophenyl)cyclopropyl)aMino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyriMidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
  • AR-C 126532XX
  • Ticagrelor(AR-C 126532XX
  • Ticagrelor (AZD6140)
  • (1S,2S,3R,5S)-3-(7-((1R,2S)-2-(3,4-difluorophenyl)cyclopropylaMino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyriMidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
  • (1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-D1,2-Cyclopentanediolifluorophenyl)cyclopropyl]aMino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyriMidin-3-yl]-5-(2-hydroxyethoxy)-1,2-cyclopentanediol
  • 1,2-Cyclopentanediol, 3-[7-[[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-, (1S,2S,3R,5S)-
  • Ticagrelor, >=98%
  • Ticagrelo
  • Ticargrelor
  • Ticarelor
  • Brilinta
  • Possia
  • Ticagrelor and intermediates
  • Ticagrelor Standards
  • 374693-27-5
  • 74693-27-5
  • C23H28F2N6O4S
  • 3-[7-[[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]aMino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyriMidin-3-yl]-5-(2-hydroxyethoxy)-,(1S,2S,3R,5S)-
  • Tecagrelor
  • (1S,2S,3R,5S)-3-[7-[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropylaMino]-5-(propylsulfanyl)-3H-[1,2,3]triazolo[4,5-d]pyriMidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
  • 274693-27-5
  • Ticagrelor
  • AZD6140
  • Cardiovascular APIs
  • Aromatics
  • Heterocycles
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
  • Sulfur & Selenium Compounds
Copyright 2017 © ChemicalBook. All rights reserved